small molecule

VIJOICE

ALPELISIB

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry

CompanyNovartis →View the full company profile on CliffBio

Drug detail

Brand name	VIJOICE
Active ingredient	ALPELISIB
Strength	50MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2022
Marketing status	RX

Listed patents

Patent	Expires	Type
12427141	February 2037	use U-4288
11433059	February 2037	use U-4359
8227462	April 2033	substance, product
8476268	September 2029	substance, product

Regulatory exclusivity

Code	Expires
ODE-396	April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Novartis